MIM
BPMC

Monashee Investment Management’s Blueprint Medicines BPMC Stock Holding History

Monashee Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-138,500
Closed -$11.1M – 168
2019
Q1 		$11.1M Buy
+138,500
New +$10.2M 2.55% 8
2017
Q4 		– Hold
0
– – – 12
2017
Q1 		– Sell
-80,000
Closed -$2.86M – 8
2016
Q4 		$2.24M Buy
+80,000
New +$2.41M 1.09% 37

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Monashee Investment Management's BPMC Position: Q2 2019 in Review

Monashee Investment Management sold out of Blueprint Medicines (BPMC) in Q2 2019, closing a stake of 138,500 shares — an estimated $11.1M sold.

Monashee Investment Management first reported a position in BPMC in Q4 2016 and held it in 2 quarters. The position peaked at $11.1M in Q1 2019. 220 funds tracked by Wall St. Rank hold BPMC as of Q2 2019.

  • Monashee Investment Management reported no remaining Blueprint Medicines position as of Q2 2019 after selling out during the quarter.
  • Monashee Investment Management sold 138,500 Blueprint Medicines shares in Q2 2019, an estimated $11.1M.
  • Monashee Investment Management first reported a position in Blueprint Medicines in Q4 2016 and held it in 2 quarters.
  • Monashee Investment Management's Blueprint Medicines position peaked at $11.1M in Q1 2019.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2019.

Based on Monashee Investment Management's 13F filing for Q2 2019, filed 7 Aug 2019.